Categories: AppArtificial IntelligenceDataDrugHumanOptimizePlatform
Guided by our powerful AI capabilities, Terray leverages vast high-quality data to optimize the path from discovery to transformative therapeutics.
Investors 4
Mentions in press and media 7
| Date | Title | Description |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 31.01.2025 | Madrona: $770 Million Closed For Madrona Fund X And Acceleration Fund IV | Madrona announced the closing of Fund X and Acceleration Fund IV, which will be deployed in the next several years in new companies and will support them through their life cycle.
These funds come at the start of Madrona’s 30th year of help... |
| 22.10.2024 | Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health | Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B fu... |
| 18.10.2024 | The Week’s 10 Biggest Funding Rounds: X-energy And Lightmatter Lead The Way | 3 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a w... |
| 17.10.2024 | Terray Therapeutics Closes $120M Series B Funding Round | Terray Therapeutics, a Los Angeles, CA-based biotechnology company improving human health by enhancing small molecule drug development, raised $120M in Series B funding.
The round was led by Bedford Ridge Capital and existing investor NVent... |
| - | Terray Therapeutics | “Terray exists to change the way experimentation and computation work together. We believe high-quality data at scale is the key to unlocking generative AI for small molecules. ” |
| - | Announcing Two Sigma Ventures III, Our New $288M Fund to Back Data-Driven Founders | We’re excited to announce the close of Two Sigma Ventures III, a $288M fund that we’ll use to continue backing early-stage technology companies (primarily Series A, plus Seed and Series B) pushing the boundaries of what’s possible with data... |
Reviews 0
